Table 2.
Proportion of children with moderate-to-severe anemia by survey time and number of previous treatments with the study drug
| Survey time | Number of previous treatments with the study drug | Arm | Age-adjusted treatment-adjusted P-value for arm differences* | |
|---|---|---|---|---|
| Azithromycin (n/N) (%) | Placebo (n/N) (%) | |||
| Baseline | 0 | 144/504 (28.6) | 172/525 (32.8) | 0.36 |
| 12 months | 0 | 26/102 (25.5) | 28/95 (29.5) | 0.36 |
| 1 | 42/160 (26.3) | 40/146 (27.4) | ||
| 2 | 54/327 (16.5) | 62/305 (20.3) | ||
| Age-adjusted P-value for number of treatments* | 0.06 | 0.38 | ||
| 24 months | 0 | 5/32 (15.6) | 5/44 (11.4) | 0.38 |
| 1 | 11/49 (22.5) | 14/54 (25.9) | ||
| 2 | 6/79 (7.6) | 18/88 (18.2) | ||
| 3 | 15/103 (14.6) | 16/134 (11.9) | ||
| 4 | 13/182 (7.1) | 14/163 (8.6) | ||
| Age-adjusted P-value for number of treatments* | 0.12 | 0.33 | ||
* Accounting for clustering at community level.